KR102582752B1 - 단백질 키나아제 억제제 - Google Patents
단백질 키나아제 억제제 Download PDFInfo
- Publication number
- KR102582752B1 KR102582752B1 KR1020197018970A KR20197018970A KR102582752B1 KR 102582752 B1 KR102582752 B1 KR 102582752B1 KR 1020197018970 A KR1020197018970 A KR 1020197018970A KR 20197018970 A KR20197018970 A KR 20197018970A KR 102582752 B1 KR102582752 B1 KR 102582752B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- compound
- compounds
- mixture
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433410P | 2016-12-13 | 2016-12-13 | |
| US62/433,410 | 2016-12-13 | ||
| US201762539785P | 2017-08-01 | 2017-08-01 | |
| US62/539,785 | 2017-08-01 | ||
| PCT/US2017/065847 WO2018111893A1 (en) | 2016-12-13 | 2017-12-12 | Protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190091312A KR20190091312A (ko) | 2019-08-05 |
| KR102582752B1 true KR102582752B1 (ko) | 2023-09-22 |
Family
ID=61829613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197018970A Active KR102582752B1 (ko) | 2016-12-13 | 2017-12-12 | 단백질 키나아제 억제제 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10479786B2 (https=) |
| EP (1) | EP3555092A4 (https=) |
| JP (1) | JP7077335B2 (https=) |
| KR (1) | KR102582752B1 (https=) |
| CN (1) | CN108473487B (https=) |
| AU (1) | AU2017375949B2 (https=) |
| CA (1) | CA3044066A1 (https=) |
| WO (1) | WO2018111893A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7077335B2 (ja) | 2016-12-13 | 2022-05-30 | プリンストン ドラッグ ディスカバリー インコーポレイテッド | プロテインキナーゼ阻害剤 |
| WO2020051424A1 (en) | 2018-09-07 | 2020-03-12 | Pic Therapeutics | Eif4e inhibitors and uses thereof |
| WO2020123277A1 (en) * | 2018-12-10 | 2020-06-18 | Princeton Drug Discovery Inc. | Protein kinase inhibitor prodrugs |
| KR102256804B1 (ko) * | 2019-02-26 | 2021-05-26 | 한국화학연구원 | N-페닐-2-(피리미딘-4-일아미노)티아졸-5-카복사미드 유도체, 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 미백 소재 조성물 |
| TW202146393A (zh) | 2020-03-03 | 2021-12-16 | 美商皮克醫療公司 | Eif4e抑制劑及其用途 |
| CA3229560A1 (en) | 2021-08-25 | 2023-03-02 | Christopher L. Vandeusen | Eif4e inhibitors and uses thereof |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104151321A (zh) | 2013-05-15 | 2014-11-19 | 复旦大学 | N-(2-氯-6-甲基苯基)-2[(2-甲基嘧啶-4-基)氨基]噻唑-5-甲酰胺化合物及其制备方法和用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1169038B9 (en) | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| WO2002050071A1 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
| US20040209930A1 (en) * | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| US20060021105A1 (en) * | 2004-07-29 | 2006-02-02 | Wilson Nick L | Ergonomic hand protection apparatus |
| PE20061394A1 (es) | 2005-03-15 | 2006-12-15 | Bristol Myers Squibb Co | Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas |
| AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| TW200906825A (en) | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| US20090076025A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched dasatinib |
| EP2222166B9 (en) | 2007-12-10 | 2012-11-07 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
| BRPI1009199A2 (pt) | 2009-03-17 | 2016-03-08 | Concert Pharmaceuticals Inc | compostos de pirazinoisoquinolina |
| WO2010144338A1 (en) * | 2009-06-08 | 2010-12-16 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
| EP2470212A4 (en) | 2009-10-01 | 2013-12-04 | Csl Ltd | METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA |
| CN101891738B (zh) | 2010-02-08 | 2011-09-28 | 南京卡文迪许生物工程技术有限公司 | 达沙替尼多晶型物及其制备方法和药用组合物 |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| WO2014011971A2 (en) | 2012-07-13 | 2014-01-16 | Concert Pharmaceuticals, Inc. | Deuterated carfilzomib |
| EP2970213A4 (en) | 2013-03-14 | 2016-09-07 | Concert Pharmaceuticals Inc | PACRITINIB DEUTÉRIÉ |
| CN104130250B (zh) | 2013-05-07 | 2016-06-22 | 郑州泰基鸿诺药物科技有限公司 | 氘代达沙替尼及其制备方法和应用 |
| IL286427B2 (en) | 2014-01-28 | 2024-08-01 | Mayo Found Medical Education & Res | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease |
| US20170224688A1 (en) | 2016-02-04 | 2017-08-10 | Acerta Pharma B.V. | Methods of Using BTK Inhibitors to Treat Dermatoses |
| WO2017168454A2 (en) * | 2016-04-02 | 2017-10-05 | Sun Pharma Advanced Research Company Limited | Novel compounds as btk inhibitors |
| JP7077335B2 (ja) * | 2016-12-13 | 2022-05-30 | プリンストン ドラッグ ディスカバリー インコーポレイテッド | プロテインキナーゼ阻害剤 |
-
2017
- 2017-12-12 JP JP2019551918A patent/JP7077335B2/ja active Active
- 2017-12-12 US US15/839,469 patent/US10479786B2/en active Active
- 2017-12-12 AU AU2017375949A patent/AU2017375949B2/en active Active
- 2017-12-12 KR KR1020197018970A patent/KR102582752B1/ko active Active
- 2017-12-12 WO PCT/US2017/065847 patent/WO2018111893A1/en not_active Ceased
- 2017-12-12 EP EP17879997.9A patent/EP3555092A4/en active Pending
- 2017-12-12 CA CA3044066A patent/CA3044066A1/en active Pending
- 2017-12-12 US US15/839,534 patent/US20180099961A1/en not_active Abandoned
- 2017-12-12 US US15/839,332 patent/US10174018B2/en active Active
- 2017-12-12 CN CN201780002746.8A patent/CN108473487B/zh active Active
-
2018
- 2018-11-02 US US16/179,174 patent/US10556897B2/en active Active
-
2019
- 2019-12-19 US US16/721,142 patent/US11236080B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104151321A (zh) | 2013-05-15 | 2014-11-19 | 复旦大学 | N-(2-氯-6-甲基苯基)-2[(2-甲基嘧啶-4-基)氨基]噻唑-5-甲酰胺化合物及其制备方法和用途 |
Non-Patent Citations (1)
| Title |
|---|
| Drug Metabolism & Disposition, 2009, 제37권, 제6호, 페이지 1242-1250 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3044066A1 (en) | 2018-06-21 |
| US20190071437A1 (en) | 2019-03-07 |
| US10556897B2 (en) | 2020-02-11 |
| JP7077335B2 (ja) | 2022-05-30 |
| CN108473487B (zh) | 2021-08-03 |
| US10479786B2 (en) | 2019-11-19 |
| US11236080B2 (en) | 2022-02-01 |
| US20180099959A1 (en) | 2018-04-12 |
| JP2020503376A (ja) | 2020-01-30 |
| CN108473487A (zh) | 2018-08-31 |
| AU2017375949B2 (en) | 2021-09-09 |
| US10174018B2 (en) | 2019-01-08 |
| AU2017375949A1 (en) | 2019-05-23 |
| EP3555092A4 (en) | 2020-05-13 |
| US20200123148A1 (en) | 2020-04-23 |
| KR20190091312A (ko) | 2019-08-05 |
| EP3555092A1 (en) | 2019-10-23 |
| US20180099961A1 (en) | 2018-04-12 |
| US20180099960A1 (en) | 2018-04-12 |
| WO2018111893A1 (en) | 2018-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102582752B1 (ko) | 단백질 키나아제 억제제 | |
| US10350210B2 (en) | EGFR and ALK dual inhibitor | |
| EP2493313B1 (en) | Kinase inhibitors | |
| US10596174B2 (en) | Pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| EP2727918B1 (en) | Compounds and Compositions as Protein Kinase Inhibitors | |
| CN103748096B (zh) | 作为蛋白激酶抑制剂的吡咯并嘧啶化合物 | |
| US9890163B2 (en) | Inhibitors of protein kinases | |
| IL213141A (en) | Dihydroindane amides for use in regulating protein kinase activity | |
| US20150152088A1 (en) | Alkynyl heteroaromatic compound and use thereof | |
| JP2016500118A (ja) | ヘテロアリールアルキン化合物及びその応用 | |
| JP2020023554A (ja) | ピリミジン化合物及びその医薬用途 | |
| US20150210702A1 (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| KR102685187B1 (ko) | Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 | |
| US20230114177A1 (en) | Novel deuterium-substituted pyrimidine derivative and pharmaceutical composition comprising same | |
| EP4620957A1 (en) | Imidazo[4,5-b]pyridin-7-amine compounds binding aurora kinase a and uses thereof | |
| HK1191936B (en) | Compounds and compositions as protein kinase inhibitors | |
| HK1167390B (en) | Compounds and compositions as protein kinase inhibitors | |
| HK1163054B (en) | Preparation method of dihydroindene amide compounds their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190701 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201210 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20221005 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230623 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230920 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20230920 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |